Developed in partnership with Orbicular Pharmaceutical Technologies, the injection is indicated for adults with obesity or those who are overweight with at least one weight-related comorbidity. It also targets risk reduction for non-fatal myocardial infarction in patients with established cardiovascular disease. The approval marks a significant expansion of the Toronto-based company’s portfolio, which already includes a recently authorized semaglutide injection for type 2 diabetes.

Martin Arès, President of Apotex Canada, noted that the move aligns with the firm’s five-decade history of increasing access to affordable therapeutic options. Dr. M. S. Mohan, Managing Director at Orbicular, credited the achievement to the technical strength of their peptide development platform. Healthcare providers are directed to the official product monograph for complete clinical data regarding patient monitoring and potential adverse reactions.